CASMED Reports 2017 Fourth-Quarter and Full-Year Financial Results

U.S. FORE-SIGHT sales increased 18% in Q4 on record 80 placements

Conference Call Begins Today at 10:00 a.m. Eastern Time

BRANFORD, Conn., March 14, 2018 (GLOBE NEWSWIRE) — CAS Medical Systems, Inc. (NASDAQ:CASM) (CASMED), a leader in medical products for non-invasive patient monitoring of tissue oxygenation, today reported financial results for the three and 12 months ended December 31, 2017. 

Net sales from continuing operations for the fourth quarter of 2017 were $5.1 million, up 11% from $4.6 million for the fourth quarter of 2016.  The Company incurred a net loss applicable to common stockholders of $1.9 million, or $0.07 per share, for both periods.

In July 2017, the Company sold its NIBP product line and has reclassified those results to discontinued operations for the three and 12 months ended December 31, 2017 and 2016.

Highlights for the fourth quarter of 2017 compared with the fourth quarter of 2016 include the following:

  • Total FORE-SIGHT cerebral oximetry sales increased 12% to $5.0 million.
  • U.S. FORE-SIGHT cerebral oximetry sales increased 18% to $4.3 million. 
  • Total FORE-SIGHT sensor sales increased 7%, and U.S. FORE-SIGHT sensor sales increased 8%.
  • A net 110 FORE-SIGHT cerebral oximeters were shipped worldwide. A record net 80 monitors shipped in the U.S., bringing the installed base of U.S. monitors to 1,318, as of December 31, 2017, up 18% from the prior year. 
  • The Company’s year-end cash balance plus cash available under its line of credit was $7.5 million.

Management Commentary

“We finished 2017 with a strong quarter that featured an 18% increase in U.S. FORE-SIGHT sales and a record 80 domestic monitors shipped,” said Thomas M. Patton, President and Chief Executive Officer of CASMED.  “Our domestic growth was driven by higher productivity from our upgraded sales organization, as our newer sales representatives gained tenure.  Additionally, the IDN and GPO initiatives we implemented are proving effective in both retaining customers and winning new accounts.  Importantly, we continue to benefit from the superiority of our FORE-SIGHT technology and its best-in-class cerebral oximetry measurements and gained a record 22 new accounts in the quarter, with most coming from competitive wins.  In fact, over the past 12 months, approximately two-thirds of our new accounts have followed competitive head-to-head clinical evaluations.

“I’m pleased to report that the momentum we experienced in late 2017 in our U.S. FORE-SIGHT business has continued into this year, giving us confidence in achieving the 2018 financial outlook we introduced in January,” he added.  “Our expectations continue to be for U.S. FORE-SIGHT sales for 2018 to increase in the low-teen percentages, driven by a mid-teens percentage growth in domestic sensor sales, with international sales expected to decline slightly, resulting in  2018 total FORE-SIGHT revenues increasing in the low double-digits over the prior year.”

Fourth-Quarter Financial Results

Net sales from continuing operations for the fourth quarter of 2017 increased 11% to $5.1 million from $4.6 million for the fourth quarter of 2016. Total FORE-SIGHT oximetry sales for the fourth quarter of 2017 increased 12% to $5.0 million from $4.5 million in the prior-year period, and total FORE-SIGHT disposable sensor sales for the fourth quarter of 2017 increased 7% to $4.3 million from $4.0 million.  U.S. FORE-SIGHT sales for the fourth quarter of 2017 increased 18% to $4.3 million from $3.7 million, and U.S. FORE-SIGHT disposable sensor sales for the fourth quarter increased 8% to $3.8 million from $3.5 million. International FORE-SIGHT sales for the fourth quarter of 2017 were $0.7 million versus $0.8 million for the fourth quarter of 2016.

The operating loss for the fourth quarter of 2017 was $1.2 million, an improvement of $0.3 million from an operating loss of $1.5 million for the fourth quarter of 2016.  Higher sales and lower operating expenses were responsible for the improvement. Operating expenses for the fourth quarter of 2017 decreased 6% to $4.0 million from $4.2 million in the prior-year period.  Gross profit margin for the fourth quarter of 2017 was 53.8%, compared with 60.0% for the prior-year period, largely due to the unfavorable product mix from increasing levels of monitor sales at lower profit margins consistent with the Company’s strategy to consign fewer monitors.

Full-Year Financial Results

Net sales from continuing operations of $18.8 million for 2017 finished slightly ahead of the  $18.7 million recorded for 2016.  Total FORE-SIGHT oximetry sales for 2017 increased less than 1% to $18.1 million from $18.0 million for 2016, and total FORE-SIGHT disposable sensor sales for 2017 were up 3% to $16.4 million from $15.9 million for the prior year.  U.S. FORE-SIGHT sales for 2017 increased 5% to $15.5 million from $14.7 million in 2016, and U.S. FORE-SIGHT disposable sensor sales for 2017 increased 3% to $14.3 million from $13.8 million. International FORE-SIGHT sales for 2017 were $2.6 million, compared with $3.3 million for 2016, generally reflecting lower sales of monitors to a large distributor in Asia.

The operating loss for 2017 was $6.4 million, compared with an operating loss of $6.3 million for 2016, with the slight increase due primarily to higher cost of sales, partially offset by a 1% reduction in operating expenses. Gross profit margin was 54.7% for 2017, compared with 56.2% for 2016, primarily due to lower monitor pricing.

Cash, cash equivalents, and available borrowings under the line-of-credit were $7.5 million as of December 31, 2017.

Conference Call Information

CASMED will host a conference call beginning at 10:00 a.m. Eastern time today to discuss these results and answer questions. Conference call dial-in information is as follows:

  • U.S. callers: (866) 239-5859
  • International callers: (702) 495-1913

Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Company’s website at http://corporate.casmed.com/.

A telephone replay will be available from 1:00 p.m. Eastern time on March 14, 2018, through 11:59 p.m. Eastern Time on March 28, 2018.  Replay dial-in information is as follows:

  • U.S. callers: (855) 859-2056 
  • International callers: (404) 537-3406 
  • Conference ID number (U.S. and international callers): 4797418
  • The replay will also be available at www.casmed.com.

About CASMED® – Monitoring What’s Vital

CASMED’s vision is that “No patient is harmed from undetected tissue hypoxia.”  Our FORE-SIGHT® Cerebral Oximeters provide a highly accurate, non-invasive measurement of tissue oxygenation in the brain.  Direct monitoring of tissue oxygenation can provide clinicians with a superior and powerful tool to alert them to otherwise unrecognized and dangerous hypoxia, or low levels of oxygen, in the brain and other tissue, thereby empowering them to improve patient care.  For further information regarding CASMED, visit the Company’s website at www.FORE-SIGHT.com.

Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, the impact of any product liability or other adverse litigation, working capital and availability of capital, commercialization and technological difficulties, the impact of actions and events involving key customers, vendors, lenders, competitors, and other risks detailed in the Company’s Form 10-K for the year ended December 31, 2016, and other subsequent Securities and Exchange Commission filings.

Such statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release, the terms “anticipate”, “believe”, “estimate”, “expect”, “guidance”, “may”, “objective”, “plan”, “possible”, “potential”, “project”, “will”, and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information, or otherwise.

Company Contact
CAS Medical Systems, Inc.
Jeffery A. Baird
Chief Financial Officer
(203) 315-6303
ir@casmed.com

Investors
LHA Investor Relations
Bruce Voss / Jody Cain
(310) 691-7100
bvoss@lhai.com
jcain@lhai.com 

 

(Tables to follow)

CAS MEDICAL SYSTEMS, INC.
STATEMENTS OF OPERATIONS
Unaudited
                 
    Three Months Ended   Twelve Months Ended
    Dec. 31, 2017   Dec. 31, 2016   Dec. 31, 2017   Dec. 31, 2016
                 
  Net sales from continuing operations $   5,121,475     $   4,596,813     $   18,763,136     $   18,674,146  
                 
  Cost of sales     2,367,512         1,839,878         8,505,010         8,175,487  
  Gross profit     2,753,963         2,756,935         10,258,126         10,498,659  
                 
  Operating expenses:              
    Research and development   785,362         722,987         3,234,101          3,272,718  
    Selling, general and administrative   3,207,718         3,517,890         13,418,332         13,569,939  
    Total operating expenses   3,993,080         4,240,877         16,652,433          16,842,657  
                 
  Operating loss     (1,239,117 )       (1,483,942 )       (6,394,307 )       (6,343,998 )
                 
    Interest expense     277,470         262,763         1,076,913         1,048,207  
    Other income   (127 )        (8,949 )     (513 )     (42,522 )
  Loss from continuing operations
  before income taxes
    (1,516,460 )       (1,737,756 )       (7,470,707 )       (7,349,683 )
    Income tax expense (benefit)     37,336         18,692         (1,745,441 )       (1,424,067 )
  Loss from continuing operations      (1,553,796 )       (1,756,448 )       (5,725,266 )       (5,925,616 )
  Discontinued operations:              
    Income from discontinued operations     40,000          206,310         745,396         1,277,415  
    (Loss) gain on sale of discontinued operations     –          (25,049 )       4,388,254         2,911,016  
    Income tax (benefit) expense     (37,336 )       (18,692 )       1,745,441         1,424,067  
  Income from discontinued operations     77,336          199,953         3,388,209          2,764,364  
  Net loss     (1,476,460 )       (1,556,495 )       (2,337,057 )       (3,161,252 )
    Preferred stock dividend accretion      407,681          380,350          1,589,134          1,482,595  
  Net loss applicable to common stockholders $   (1,884,141 )   $   (1,936,845 )   $   (3,926,191 )   $   (4,643,847 )
                 
  Loss per common share from continuing              
    operations – basic and diluted $   (0.07 )   $   (0.08 )   $   (0.27 )   $   (0.28 )
                 
  Income per common share from discontinued              
    operations – basic and diluted $   0.00     $   0.01     $   0.13     $   0.11  
                 
  Per share basic and diluted net loss applicable              
    to common stockholders: $   (0.07 )   $   (0.07 )   $   (0.14 )   $   (0.17 )
                 
  Weighted-average number of common              
    shares outstanding:              
    Basic and diluted     27,351,338         26,849,344         27,260,688         26,826,792  

 
CAS MEDICAL SYSTEMS, INC.
  BALANCE SHEETS
  Unaudited
           
           
             
      December 31,   December 31,  
        2017     2016  
           
Cash and cash equivalents $   5,652,996     $   5,488,706    
Accounts receivable       2,918,950         2,958,551    
Notes and other receivables     15,012         557,217    
Inventories       1,076,261         1,373,864    
Other current assets       338,067         322,148    
Assets associated with discontinued operations     –          675,019    
  Total current assets       10,001,286         11,375,505    
             
Property and equipment     8,251,236         8,743,011    
Less accumulated depreciation     (6,080,350 )       (6,182,586 )  
          2,170,886         2,560,425    
             
Intangible and other assets, net     802,391         788,036    
  Total assets   $   12,974,563     $   14,723,966    
             
             
Accounts payable   $   691,596     $   1,027,911    
Accrued expenses       1,651,873         2,201,965    
Notes payable       86,079         70,015    
Current portion of long-term debt,
  less unamortized debt issuance costs
    2,733,831         840,471    
Liabilities associated with discontinued operations     35,000         177,990    
  Total current liabilities     5,198,379         4,318,352    
             
Deferred gain on sale and leaseback of property     –          91,603    
Long-term debt, less current portion,
  less unamortized debt issuance costs
    4,943,195         6,580,851    
Other long-term liabilities     320,000         320,000    
  Total liabilities       10,461,574         11,310,806    
             
Series A convertible preferred stock     8,802,000         8,802,000    
Series A exchangeable preferred stock     5,135,640         5,135,640    
Common stock       114,487         109,715    
Additional paid-in capital     31,989,207         30,557,093    
Treasury stock       (101,480 )       (101,480 )  
Accumulated deficit       (43,426,865 )       (41,089,808 )  
  Total stockholders’ equity     2,512,989         3,413,160    
             
  Total liabilities & stockholders’ equity $   12,974,563     $   14,723,966